DEFM14A: Aadi Bioscience to Sell FYARRO Business to Kaken Investments for $100 Million; Stockholder Vote Scheduled

Aadi Bioscience plans to divest its FYARRO business to Kaken Investments for $100 million in cash, pending stockholder approval, and will focus on developing ADC Programs.

Summary

• Aadi Bioscience is seeking stockholder approval for the sale of its FYARRO business to Kaken Investments for $100 million in cash.
• The transaction is expected to close in the first half of 2025, pending stockholder approval and other closing conditions.
• Aadi plans to use the proceeds to develop ADC Programs licensed from WuXi Biologics.
• Stockholders will also vote on a PIPE financing proposal to issue shares and warrants to support the WuXi Biologics license agreement.
• An amendment to the Aadi Bioscience, Inc. 2021 Equity Incentive Plan will also be voted on to increase the number of shares available for issuance.
• A special meeting of stockholders is scheduled for February 28, 2025, to vote on these proposals.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the divestiture provides capital, it also means losing the only revenue-generating asset. The focus on ADC Programs is a positive, but they are early-stage and risky.

Positives

• The divestiture provides Aadi with $100 million in cash, strengthening its financial position.
• Focus shifts to developing ADC Programs, potentially offering a new growth area.
• The PIPE financing will provide additional capital to fund the ADC Programs.
• The proposed equity plan increase will allow Aadi to attract and retain key personnel.

Negatives

• The company will no longer own or operate the FYARRO business, its only revenue-generating asset.
• If the Divestiture Proposal fails, Aadi may be required to pay Kaken a termination fee of $3.5 million.
• Stockholders will experience significant dilution if the PIPE Financing Proposal is approved.
• The ADC Programs are in the early stages of development and may not be successful.

Risks

• The divestiture is subject to stockholder approval and other closing conditions and may not be completed.
• The pendency of the divestiture could have an adverse effect on Aadi's business and results of operations.
• The company is restrained from soliciting other acquisition proposals during the pendency of the divestiture.
• The company will incur significant expenses in connection with the divestiture, regardless of whether the divestiture is completed.
• The company will not have any approved products and its pipeline will comprise solely of preclinical assets.
• The ADC Programs have never been tested in humans.
• The company is currently dependent on single-source suppliers for its product candidates and their components.
• The company is subject to the risks associated with doing business in China.

Future Outlook

Aadi plans to focus on developing the ADC Programs licensed from WuXi Biologics, with potential IND submissions expected in the next 12-24 months.

Management Comments

• Aadi expects to use the collective proceeds from the divestiture and PIPE financing to develop the ADC Programs and for general corporate purposes.
• If the PIPE Financing Proposal fails, Aadi's board will need to assess whether to pay the balance of the upfront license fee or allow the License Agreement to terminate.
• Following the completion of the Divestiture, the FYARRO Business will be owned and operated by Kaken, and Aadi will have no interest in, and receive no income from, the FYARRO Business.

Industry Context

The announcement reflects a strategic shift in the biopharmaceutical industry, with companies focusing on specific therapeutic areas and leveraging partnerships for development and commercialization.

Comparison to Industry Standards

• The $100 million upfront payment for the FYARRO business is within the range of comparable transactions in the pharmaceutical industry.
• The milestone payments and royalties for the ADC Programs are consistent with industry standards for licensing agreements.
• The PIPE financing is a common method for raising capital in the biopharmaceutical industry, particularly for companies in the development stage.
• The company is competing with AbbVie, Daiichi Sankyo, Eli Lilly, and Roche in the ADC field.

Related Party Transactions

• Certain directors, affiliated funds of directors, and an executive officer of Aadi have committed to purchase shares and warrants in the PIPE Financing.

Stakeholder Impact

• Shareholders will vote on the proposed divestiture and PIPE financing, impacting the company's future direction.
• Employees may be affected by the restructuring and shift in focus to ADC Programs.
• Customers of FYARRO will see a change in ownership and management of the product.
• Suppliers and creditors may be impacted by the change in the company's business strategy.

Next Steps

• Aadi stockholders will vote on the divestiture, PIPE financing, and equity plan increase proposals at a special meeting on February 28, 2025.
• If approved, the divestiture is expected to close in the first half of 2025.
• Aadi will then focus on developing the ADC Programs, with potential IND submissions expected in the next 12-24 months.

Key Dates

Keywords

Divestiture, FYARRO, PIPE Financing, ADC Programs, Stockholder Approval, KAKEN INVESTMENTS, WuXi Biologics, Equity Plan Increase, Aadi Bioscience